Advertisement
U.S. markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real Time Price. Currency in USD
13.05+0.05 (+0.38%)
At close: 04:00PM EST
13.03 -0.02 (-0.15%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close13.00
Open13.05
Bid13.08 x 3200
Ask13.09 x 2900
Day's Range12.93 - 13.15
52 Week Range7.09 - 13.35
Volume7,413,788
Avg. Volume10,442,703
Market Cap14.629B
Beta (5Y Monthly)1.01
PE Ratio (TTM)N/A
EPS (TTM)-0.50
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 27, 2017
1y Target Est14.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
17% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for TEVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Teva Pharmaceutical Industries
    Analyst Report: Teva Pharmaceutical Industries LimitedTeva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
    Rating
    Fair Value
    Economic Moat
    23 days agoMorningstar
View more
  • Business Wire

    Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

    TEL AVIV, Israel & PARSIPPANY, N.J., February 20, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced positive safety, tolerability, and pharmacokinetic data for its anti-TL1A (TEV-’574) asset, a potentially best-in-class human IgG1 monoclonal antibody that targets the tumor necrosis factor (TNF)-like ligand 1A (TL1A) and is designed to offer both anti-inflammatory and anti-fibrotic effects.1-3

  • Reuters

    UPDATE 2-Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO

    Teva Pharmaceutical Industries will remain a single company for generic and branded drugs, and expects to see significant interest in its active pharmaceutical ingredients business that it plans to divest, its head said on Tuesday. There has been speculation that Israel-based Teva - the world's largest generic drug maker - would split into two companies handling both the increasingly competitive generics business and its own branded drugs. However, the company will stay unified, and "from an infrastructure point of view, (the two businesses) complement each other incredibly well," Chief Executive Richard Francis said at a news briefing.

  • Insider Monkey

    Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript

    Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript February 15, 2024 Corcept Therapeutics Incorporated beats earnings expectations. Reported EPS is $0.28, expectations were $0.25. Corcept Therapeutics Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Corcept […]